Evidence map›Paper›PMID 34439871›Full record

ArticleBiomolecules2021

Toll-like Receptor 2 as a Marker Molecule of Advanced Ovarian Cancer.

Małgorzata Sobstyl, Paulina Niedźwiedzka-Rystwej, Rafał Hrynkiewicz, Dominika Bębnowska, Izabela Korona-Głowniak, Marcin Pasiarski, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Stanisław Góźdź, Anna Sobstyl and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Multi-omics analysis identifieTranslational cancer research · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Małgorzata SobstylDepartment of Gynecology and Gynecological Endocrinology, Medical University of Lublin, 20-037 Lublin, Poland.
Paulina Niedźwiedzka-RystwejInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0003-4065-3842
Rafał HrynkiewiczInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0002-0688-6928
Dominika BębnowskaInstitute of Biology, University of Szczecin, 71-412 Szczecin, Poland.ORCID 0000-0003-3689-2381
Izabela Korona-GłowniakDepartment of Pharmaceutical Microbiology, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0003-1634-0387
Marcin PasiarskiDepartment of Immunology, Faculty of Health Sciences, Jan Kochanowski University, 25-317 Kielce, Poland.
Barbara Sosnowska-PasiarskaDepartment of Oncocardiology, Holy Cross Cancer Centre, 25-734 Kielce, Poland.ORCID 0000-0003-3536-8035
Jolanta Smok-KalwatDepartment of Clinical Oncology, Holy Cross Cancer Centre, 25-734 Kielce, Poland.
Stanisław GóźdźDepartment of Clinical Oncology, Holy Cross Cancer Centre, 25-734 Kielce, Poland.
Anna SobstylDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.
Wojciech PolkowskiDepartment of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080 Lublin, Poland.ORCID 0000-0001-6455-5636
Jacek RolińskiDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0003-4841-6120
Ewelina GrywalskaDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-0451-4741
Medical University of Lublin · PLUniversity of Szczecin · PLHoly Cross University · PLJan Kochanowski University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is a global problem that affects women of all ages. Due to the lack of effective screening tests and the usually asymptomatic course of the disease in the early stages, the diagnosis is too late, with the result that less than half of the patients diagnosed with ovarian cancer (OC) survive more than five years after their diagnosis. In this study, we examined the expression of TLR2 in the peripheral blood of 50 previously untreated patients with newly diagnosed OC at various stages of the disease using flow cytometry. The studies aimed at demonstrating the usefulness of TLR2 as a biomarker in the advanced stage of ovarian cancer. In this study, we showed that TLR2 expression levels were significantly higher in women with more advanced OC than in women in the control group. Our research sheds light on the prognostic potential of TLR2 in developing new diagnostic approaches and thus in increasing survival in patients with confirmed ovarian cancer.

Indexed as

Carcinoma, Ovarian EpithelialOvarian NeoplasmsAgedBiomarkers, TumorCase-Control StudiesFemaleHumansMiddle AgedPrognosisToll-Like Receptor 2Biomarkers, TumorTLR2 protein, humanToll-Like Receptor 2biomarkerexpressionovarian cancerreceptorTLR2Toll-like receptor

Identifiers

PMID34439871
PMCPMC8394498
OpenAlexW3195741617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.